Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 12/20 | 0.51 |
| ▸ | DHPS | P49366 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077773 | 0.87 | HTR3A (0.54) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4085886 | 0.86 | HTR3A (0.57) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4077756 | 0.86 | HTR3A (0.50) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4084284 | 0.83 | HTR3A (0.47) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4074995 | 0.81 | CYP11B1 (0.49) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4082461 | 0.79 | KCNH2 (0.45) | HTR3AKCNH2 | |
| SCHEMBL4074335 | 0.77 | HTR3A (0.58) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4074754 | 0.73 | HTR3A (0.53) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4079344 | 0.72 | HTR3A (0.62) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4079345 | 0.72 | HTR3A (0.62) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566727-B2 | 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor | ASTRAZENECA AB | 2009-07-28 | — | — | US | claimed |
| US-20070213342-A1 | Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | claimed |
| US-7566727-B2 | 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor | ASTRAZENECA AB | 2009-07-28 | — | — | US | disclosed |
| US-20070213342-A1 | Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213342-A1 | Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor | CHRNA1, CHRNA7, CHRNE | HTR3A 68/4885DHPS 1458/4885HTR3B 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.